PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments

TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) — via IBN PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. This comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in ASD therapeutics, and its commitment to addressing unmet needs within the ASD community.

Click here to view the presentation.

The new presentation, available on the PaxMedica website, outlines the company’s focused pipeline, including its leading investigational drug, PAX-101. With its approach to targeting the core symptoms of ASD, PaxMedica is leading the way in developing treatments that offer hope to millions of families seeking effective interventions.

“PaxMedica is pleased to share our vision and progress with the wider community,” said Howard Weisman, Chairman and CEO of PaxMedica. “We believe that our work has the potential to transform the treatment landscape for ASD, offering a new horizon of hope and support for affected individuals and their loved ones.”

The presentation details PaxMedica’s mission to bridge the gap in ASD treatment options through innovative research and development. It also provides insights into the anticipated company’s milestones, upcoming clinical trials, and the broader impact its therapies could have on public health.

“PaxMedica’s commitment goes beyond developing novel therapeutics; it’s about creating a world where individuals with ASD can thrive,” added Buzz Woods, Director of Communications at PaxMedica. “Our new presentation captures the essence of our drive and the transformative potential of our therapies.”

For more information about PaxMedica and to access the presentation, please visit

About PaxMedica

PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (APT) aimed at addressing a range of challenging neurologic disorders. Our comprehensive portfolio encompasses a spectrum of conditions, including neurodevelopmental disorders such as Autism Spectrum Disorder (ASD), as well as other critical areas within the neurology field. We are dedicated to the continuous development and evaluation of our pioneering program, PAX-101-an intravenous suramin formulation that lies at the heart of our efforts, particularly focused on innovative ASD treatment solutions. Our ongoing research initiatives not only prioritize the needs of ASD patients but also extend to exploring potential therapeutic applications for related conditions. To learn more about our transformative work, please visit

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at and by following PaxMedica on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements reflect our current view about future events. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue” or similar expressions. These forward-looking statements include our anticipated clinical program, the timing and success of our anticipated data announcements, pre-clinical and clinical trials and regulatory filings, statements about the strength of our balance sheet. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of the Company’s product development and clinical trials, risk of insufficient capital resources, cash funding and cash burn and risks associated with intellectual property and infringement claims. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company’s “Risk Factors” section and other sections in its most recent Annual Report on Form 10-K, and subsequent quarterly and other filings with the U.S. Securities and Exchange Commission.


PaxMedica, Inc.
 303 S Broadway,
 Suite 125.
 Tarrytown, NY 10591

Media Contact

Investor Contact
 Scott McGowan
 InvestorBrandNetwork (IBN)
 Phone: 310.299.1717

SOURCE: PaxMedica, Inc.

error: Content is protected !!